Our journey began in late 2022 when founder and CEO Lewis James Donohue, a biomedical scientist with a passion for peptide technology, established a laboratory testing peptide purity. His findings revealed that peptide quality in UK and EU markets was compromised, with some companies claiming 99% purity when actual levels ranged from 85.67% to 97%. This significantly impacts biomedical research, as reliable experiments require accurate purity data, without which the true potential of peptides may never be fully understood